2016 ACR/ARHP Annual Meeting

November 11-16, 2016. Washington, DC.

View by Number View by Title View Sessions

View by Date

Abstract Number: 1452

18 F-FDG PET Imaging: An In Vivo quantitative Drug Screening Tool for Novel Antiinflammatory Therapies
Abstract Number: 1453

Treatment of BAFF Transgenic Mice with Anti-TNF: Monoclonals Are Associated with a Higher Risk of Lymphoma Than Etanercept
Abstract Number: 1454

Combination of the SYK Inhibitor, GS-9876, with a JAK Inhibitor Increases Efficacy in a Chronic Rat Model of Collagen-Induced Arthritis
Abstract Number: 1455

Collagen-Induced Arthritis and Uveitis in Mice Lacking TNF Receptors
Abstract Number: 1456

Identification of a Unique Population of B220hi B-Cells in Inflamed Lymph Nodes (Bin) As a Potential Biomarker of Arthritic Progression in the Tumor Necrosis Factor Transgenic Mouse Model of Rheumatoid Arthritis
Abstract Number: 1457

Early Onset Morbidity and Mortality in Female Tumor Necrosis Factor Transgenic Mice with Inflammatory-Erosive Arthritis and Interstitial Lung Disease
Abstract Number: 1458

Intraadrenal Dendritic Cells Inhibit Corticosterone Response during Collagen-Induced Arthritis – a Role for IL-1β and CXC Chemokines?
Abstract Number: 1459

Enhanced Efficacy of Early Vs. Late IL-1β Antagonism in Murine Arthritis Mediated By Deficiency of the IL-1 Receptor Antagonist IL-1ra
Abstract Number: 1460

Suppression of Cholesterol Levels and Impairment in Cholesterol Efflux By HDL in K/BxN Mice Is Associated with a Specific Cytokine/Chemokine Profile
Abstract Number: 1461

Modification of Proteins with Malondialdehyde-Acetaldehyde and Citrulline Elicit Antibody Responses in DBA/1J Mice
Abstract Number: 1462

Magnesium Is a New Mediator Arthritis Severity and Joint Damage
Abstract Number: 1463

Helminths Based Tuftsin-Phosphorylcholine Prevent Development of Mouse Collagen Induced Arthritis, While Maintaining Normal Gut Microbiota
Abstract Number: 1464

Utility of Relative Cardiovascular Risk Score Scales and Vascular Age Predictors in Patients with Reumathoid Arthritis UNDER 50 YEARS of Age
Abstract Number: 1465

Utility of Relative Cardiovascular Risk Score Scales in Patients UNDER the Age of 50 and Its Association with the Presence of Carotid Atherosclerosis in the Ultrasound
Abstract Number: 1466

Cardiovascular Risk Assessment in Persons with Rheumatoid Arthritis: A Correlative Study of Non-Invasive Arterial Health Testing with the Inflammatory Burden of Disease

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].